ALBUQUERQUE, NM — January 15, 2025 — High Desert Biotech NM announced today the appointment of Dr. Sandra Reyes as Chief Executive Officer, effective immediately. Reyes brings more than 20 years of biopharmaceutical leadership experience to the role, most recently serving as President of Clinical Development at Denver-based Meridian Therapeutics Group. Reyes will oversee all corporate operations and lead the company's strategic vision as High Desert Biotech NM advances its pipeline of small-molecule therapies targeting rare inflammatory diseases. Her arrival comes at a pivotal moment, as the company prepares to initiate Phase II clinical trials for its lead candidate, HDB-114, in the second quarter of 2025. "Sandra's track record of shepherding therapies from discovery through commercialization makes her the ideal leader to guide High Desert Biotech into its next chapter," said Board Chairman Thomas Archuleta. "Her deep regulatory expertise and established relationships within the investment community will be invaluable as we approach critical milestones." Reyes holds a doctorate in molecular pharmacology from the University of Arizona and an MBA from the University of New Mexico Anderson School of Management. She has previously led teams responsible for three FDA-approved therapies and has secured more than $340 million in institutional funding throughout her career. "New Mexico is rapidly emerging as a serious hub for life sciences innovation, and I am honored to lead a company that reflects that momentum," Reyes said. **About High Desert Biotech NM:** High Desert Biotech NM is an Albuquerque-based biopharmaceutical company focused on developing targeted therapies for rare inflammatory and autoimmune diseases. For more information, visit www.highdesertbiotechnm.com. ---